Literature DB >> 19265131

NK cells recognize and kill human glioblastoma cells with stem cell-like properties.

Roberta Castriconi1, Antonio Daga, Alessandra Dondero, Gianluigi Zona, Pietro Luigi Poliani, Alice Melotti, Fabrizio Griffero, Daniela Marubbi, Renato Spaziante, Francesca Bellora, Lorenzo Moretta, Alessandro Moretta, Giorgio Corte, Cristina Bottino.   

Abstract

In this study, cancer cells were isolated from tumor specimens of nine glioblastoma patients. Glioblastoma cells, cultured under suitable culture conditions, displayed markers typical of neural stem cells, were capable of partial multilineage differentiation in vitro, and gave origin to infiltrating tumors when orthotopically injected in NOD/SCID mice. These cells, although resistant to freshly isolated NK cells, were highly susceptible to lysis mediated by both allogeneic and autologous IL-2 (or IL-15)-activated NK cells. Indeed, all stem cell-cultured glioblastoma cells analyzed did not express protective amounts of HLA class I molecules, while expressing various ligands of activating NK receptors that triggered optimal NK cell cytotoxicity. Importantly, glioblastoma stem cells expressed high levels of PVR and Nectin-2, the ligands of DNAM-1-activating NK receptor.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19265131     DOI: 10.4049/jimmunol.0802845

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  135 in total

1.  Preclinical evaluation of ex vivo expanded/activated γδ T cells for immunotherapy of glioblastoma multiforme.

Authors:  Nichole L Bryant; G Yancey Gillespie; Richard D Lopez; James M Markert; Gretchen A Cloud; Catherine P Langford; Hilal Arnouk; Yun Su; Hilary L Haines; Catalina Suarez-Cuervo; Lawrence S Lamb
Journal:  J Neurooncol       Date:  2010-06-10       Impact factor: 4.130

2.  Stem-like tumor-initiating cells isolated from IL13Rα2 expressing gliomas are targeted and killed by IL13-zetakine-redirected T Cells.

Authors:  Christine E Brown; Renate Starr; Brenda Aguilar; Andrew F Shami; Catalina Martinez; Massimo D'Apuzzo; Michael E Barish; Stephen J Forman; Michael C Jensen
Journal:  Clin Cancer Res       Date:  2012-03-08       Impact factor: 12.531

3.  The interaction of human natural killer cells with either unpolarized or polarized macrophages results in different functional outcomes.

Authors:  Francesca Bellora; Roberta Castriconi; Alessandra Dondero; Giorgio Reggiardo; Lorenzo Moretta; Alberto Mantovani; Alessandro Moretta; Cristina Bottino
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-30       Impact factor: 11.205

4.  Resistance to cytotoxicity and sustained release of interleukin-6 and interleukin-8 in the presence of decreased interferon-γ after differentiation of glioblastoma by human natural killer cells.

Authors:  Anna K Kozlowska; Han-Ching Tseng; Kawaljit Kaur; Paytsar Topchyan; Akihito Inagaki; Vickie T Bui; Noriyuki Kasahara; Nicholas Cacalano; Anahid Jewett
Journal:  Cancer Immunol Immunother       Date:  2016-07-20       Impact factor: 6.968

Review 5.  Concise Review: Targeting Cancer Stem Cells Using Immunologic Approaches.

Authors:  Qin Pan; Qiao Li; Shuang Liu; Ning Ning; Xiaolian Zhang; Yingxin Xu; Alfred E Chang; Max S Wicha
Journal:  Stem Cells       Date:  2015-05-13       Impact factor: 6.277

6.  NK cells control breast cancer and related cancer stem cell hematological spread.

Authors:  Rossana Tallerico; Laura Conti; Stefania Lanzardo; Rosa Sottile; Cinzia Garofalo; Arnika K Wagner; Maria H Johansson; Costanza Maria Cristiani; Klas Kärre; Ennio Carbone; Federica Cavallo
Journal:  Oncoimmunology       Date:  2017-02-23       Impact factor: 8.110

7.  A disintegrin and metalloproteinases 10 and 17 modulate the immunogenicity of glioblastoma-initiating cells.

Authors:  Fabian Wolpert; Isabel Tritschler; Alexander Steinle; Michael Weller; Günter Eisele
Journal:  Neuro Oncol       Date:  2013-12-09       Impact factor: 12.300

Review 8.  Cancer stem cells: Regulation programs, immunological properties and immunotherapy.

Authors:  Dingxiao Zhang; Dean G Tang; Kiera Rycaj
Journal:  Semin Cancer Biol       Date:  2018-05-09       Impact factor: 15.707

Review 9.  Targeting PVR (CD155) and its receptors in anti-tumor therapy.

Authors:  Paola Kučan Brlić; Tihana Lenac Roviš; Guy Cinamon; Pini Tsukerman; Ofer Mandelboim; Stipan Jonjić
Journal:  Cell Mol Immunol       Date:  2018-10-01       Impact factor: 11.530

10.  Recognition and killing of brain tumor stem-like initiating cells by CD8+ cytolytic T cells.

Authors:  Christine E Brown; Renate Starr; Catalina Martinez; Brenda Aguilar; Massimo D'Apuzzo; Ivan Todorov; Chu-Chih Shih; Behnam Badie; Michael Hudecek; Stanley R Riddell; Michael C Jensen
Journal:  Cancer Res       Date:  2009-11-10       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.